Selling a MedSpa in 2026: Multiples, Named Buyers, and the Aesthetic-Services Playbook

If you own a MedSpa or aesthetic clinic in 2026 — whether that is a single-location injectables-focused practice, a multi-site laser/aesthetic chain, or a regional aesthetic-services platform — the M&A market is white-hot. Skytale Group has been the most visible PE-backed consolidator, Cortes NLD and Comvest-backed platforms are rolling up, AbbVie’s Allergan Aesthetics is the strategic giant in the background, LaserAway and Ideal Image continue to acquire, and the corporate-practice-of-medicine landscape is rapidly maturing. The recurring-patient economics of injectables (Botox typically every 3-4 months, fillers every 6-12 months) make profitable MedSpas a structurally attractive platform-roll-up target.

What the asset is worth depends on three things: (1) injectables revenue percentage and patient retention (recurring injectables = the multiple-builder), (2) the operating compliance posture — MD or NP/PA supervision model, corporate-practice-of-medicine structure, state-by-state good-faith-exam compliance, scope-of-practice for injectors, and (3) per-location economics with a modern operating system. This guide gives you real multiples ranges, the named buyers transacting, and the operator-level diligence buyers will run.

Named MedSpa / aesthetic M&A events (2022-2025)

The transactions below are public or widely-disclosed deals. They show an extremely active and well-capitalized buyer pool:

The named buyer landscape

PE-backed MedSpa / aesthetic platforms (the primary buyer pool)

• Skytale Group — PE-backed, the most visible MedSpa consolidator with 100+ portfolio assets across the US. Aggressive tuck-in acquirer.
• LaserAway — PE-backed laser/aesthetic platform with 200+ centers. Continues to add locations.
• Ideal Image — NewSpring Capital-backed, 150+ centers (legacy from Steiner Leisure ownership).
• Cortes NLD — PE-backed multi-location aesthetic-services roll-up.
• Other PE-backed regional platforms: SEV Laser, Sona Med Spa, plus multiple regional aesthetic consolidators with PE backing.

Public / strategic (manufacturer-side)

• AbbVie / Allergan Aesthetics (NYSE: ABBV) — the dominant injectables / aesthetic-device manufacturer (Botox, Juvederm, CoolSculpting, SkinMedica, AlloDerm, etc.). Selectively acquires aesthetic businesses and runs manufacturer-rebate programs that materially affect MedSpa P&Ls.
• Hydrafacial / The Beauty Health Company (NASDAQ: SKIN) — equipment-platform side, post-SPAC public.
• Galderma, Merz Pharma, Revance Therapeutics — competing injectables manufacturers (Dysport, Restylane, Xeomin, Daxxify).
• Cynosure, Lutronic, Sciton, Cutera — aesthetic-device manufacturers; selective MedSpa M&A and partnership activity.

PE sponsors active in this space

• Comvest Partners, Caltius Equity Partners, NewSpring Capital, NaviMed Capital, Atlanta Capital, BlackRock-backed platforms — multiple healthcare-services and consumer-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: high injectables revenue percentage (Botox/fillers/Daxxify recurring patient base), diversified service mix (injectables + body contouring + laser + Hydrafacial + skin care), MD-supervised model with documented good-faith exams, corporate-practice-of-medicine-compliant structure, modern operating system (Aesthetic Record, PatientNow, Symplast, RepeatMD, Mangomint), Allergan / Galderma rebate program enrollment, named-brand recognition.
• Will compress or reject: corporate-practice-of-medicine compliance gaps, NP/PA scope-of-practice exposure (especially state-specific rules on injection delegation), good-faith-exam workflow failures or telehealth-only models in states that require in-person, undocumented MD relationships, single-service-line concentration (e.g., 80% laser hair removal with commodity competition), owner-injector dependence, legacy operating systems or paper charts, undisclosed sale-of-goods vs. professional-services revenue mix.

The operator-level KPI playbook buyers will diligence

Service mix and revenue composition

• Injectables percentage: Botox + filler + Daxxify + Dysport % of revenue. 40%+ injectables is the platform benchmark for premium multiples (recurring patient stickiness).
• Service-mix diversity: Injectables, body contouring (CoolSculpting, EmSculpt), laser (hair removal, IPL, fractional, picosecond), Hydrafacial / facials, skin care (medical-grade product sales), threads, IV hydration, weight management (semaglutide / tirzepatide GLP-1s if applicable and compliant).
• Average ticket per visit: Track by service line.
• Sale-of-goods vs. services split: Important for tax/COGS treatment and for compliance with state cosmetic-practice rules.

Patient mix and retention

• Active patient count: 12-month and 24-month active patient counts.
• Average annual spend per active patient: $1,500-$3,500+ for injectables-recurring patients.
• Visit frequency by service: Botox typically every 3-4 months; fillers every 6-12 months; CoolSculpting on a treatment-course basis; Hydrafacial monthly.
• Retention/lapsed-patient programs: Documented win-back workflows and metrics.

Compliance and MD/NP/PA supervision

• Medical director arrangements: Documented MD oversight, hours, credentialing, compensation. Avoid corporate-practice-of-medicine structural exposure.
• Good-faith-exam (GFE) workflow: State-specific requirements (some states require in-person GFE before injectables; others allow telehealth). Document workflow and audit trail.
• Scope of practice for injectors: State-by-state RN/NP/PA scope-of-practice and delegation rules. Documented training and credentialing for every injector.
• Standing orders and protocols: Documented standing orders for every service line, signed by medical director, current and active.
• Adverse-event tracking: Documented incident reports, complications log, malpractice insurance current.

Operating system and tech stack

• EMR / practice management: Aesthetic Record (the dominant aesthetic-specific EMR), PatientNow, Symplast, Mangomint, Boulevard. Legacy or paper systems trigger discount.
• Loyalty / RepeatMD-style programs: RepeatMD has become a dominant patient-loyalty/membership platform in aesthetics.
• Marketing stack: Documented digital marketing (Google Ads, Instagram, TikTok), referral programs, membership models.
• Manufacturer rebate programs: Allergan APG (Allergan Partner Privileges), Galderma ASPIRE, Merz Galz programs — documented enrollment and rebate accrual.

Per-location economics

• Revenue per location: Platform-benchmark single-location $1.5M+ revenue.
• EBITDA margin per location: 20-30% is healthy for well-run MedSpas; over 35% may indicate under-investment.
• Provider productivity: Injector revenue per hour, injector utilization, ticket-per-treatment metrics.
• Lease terms and footprint: Class-A retail in attractive demographic markets; long-dated leases preferred.

Dangers and traps in MedSpa M&A

1. Corporate-practice-of-medicine (CPOM) compliance

MedSpas operating in CPOM-strict states (CA, NJ, NY, TX, etc.) need a state-compliant structure: typically an MD-owned professional medical corporation (PC) and a separately-owned management services organization (MSO). Structural CPOM gaps are a binary issue for many buyers.

2. NP/PA scope-of-practice exposure

State rules on NP and PA scope of practice for injectables vary significantly. Some states allow autonomous injection; others require physician delegation, specific supervision agreements, and state-specific protocols. Document every injector’s scope and delegation.

3. Good-faith-exam (GFE) failures

Many states require a physician-led good-faith exam before initial injectables (varies by service line and patient). Telehealth-only GFE compliance is state-specific. Buyers will audit GFE workflow.

4. GLP-1 / weight-management exposure

Semaglutide and tirzepatide compounded preparations have become a MedSpa revenue line. State-specific compounding regulations, FDA enforcement on compounded GLP-1s, and unprecedented patient-safety scrutiny make this a real diligence concern. Document supplier compliance, prescription protocols, and clinical oversight.

5. Single-service-line concentration

If 60%+ of revenue is laser hair removal, your asset is competing in a commoditized space and the multiple compresses. Diversification into injectables, body contouring, and skincare is the multiple-builder.

6. Owner-injector dependence

If the owner is the primary injector and 60%+ of revenue runs through them, expect a 12-24 month earnout and a compressed multiple. Build the injector bench before going to market.

7. Manufacturer rebate compliance and revenue recognition

Allergan APG, Galderma ASPIRE, and Merz rebate accruals can be significant. Document accrual accounting cleanly and confirm program enrollment is current.

8. Legacy operating systems and patient-data continuity

If you are on paper charts or a legacy practice-management system, expect a buyer-side integration project. Aesthetic Record and PatientNow are the operator-standard EMRs.

9. Lease and demographic-market quality

Class-A retail in attractive demographic markets is the platform standard. Tertiary markets and B/C retail compress.

10. Sale-of-goods vs. professional-services revenue mix and state cosmetic-practice rules

Some states have distinct rules for sale-of-goods (skincare product) vs. medical professional services. Disclose mix cleanly and confirm regulatory compliance.

Our POV on MedSpa M&A in 2026

The honest read on the market: MedSpa M&A is one of the most active healthcare-services consolidation themes in 2026, driven by recurring-injectables economics and the maturing PE-platform infrastructure. The buyer pool is real and the multiples are real, but compliance is the gating factor.

• If you are a sub-scale single-site MedSpa, multiples are 2x-4x SDE. Buyer pool is small regional aesthetics roll-ups and the PE-backed platforms doing geographic tuck-ins.
• If you are a profitable single-location MedSpa with $500k-1.5M SDE, you are in the tuck-in sweet spot for Skytale, Cortes NLD, regional PE platforms, and LaserAway. 3.5x-6x SDE multiples; the right competitive process matters.
• If you are a small multi-site chain (2-5 locations, $1-3M EBITDA), the buyer pool widens to PE platforms directly and the strategic-manufacturer-backed players. 5x-7x EBITDA.
• If you are a mid-size regional platform (5-15 locations, $3-8M EBITDA), you are highly leveraged. 6x-9x EBITDA in a real competitive process.
• If you are a premium scale platform (15+ locations, $8M+ EBITDA, CPOM-compliant, diversified service mix, modern operating infrastructure), you are a strategic target. 8x-10x+ EBITDA achievable.

The right time to prepare is 12-18 months before going to market — lock in CPOM-compliant structure, build the injector bench, modernize EMR (Aesthetic Record / PatientNow), document GFE workflows, and diversify service mix. Compliance is non-negotiable.

Preparing your MedSpa for sale: 12-18 months out

1. Lock in CPOM-compliant structure. If you operate in a CPOM-strict state, ensure PC + MSO structure is in place and documented. Health-care counsel review.
2. Build the injector bench. Reduce owner-injector dependence. Train and develop NP/PA injectors with state-compliant scope and supervision.
3. Document MD oversight and GFE workflow. Medical director hours, credentialing, oversight visits, GFE compliance audit trail.
4. Get audited or reviewed financials. Multi-year, clean accrual, manufacturer rebate accruals documented, owner add-backs documented contemporaneously.
5. Modernize the operating system. Aesthetic Record, PatientNow, Symplast, Mangomint, or Boulevard. Document patient-data continuity.
6. Diversify service mix. Build injectables, body contouring, laser, Hydrafacial, and skin care as a balanced portfolio.
7. Enroll in manufacturer rebate programs. Allergan APG, Galderma ASPIRE, Merz Galz, Revance Daxxify partnership programs.
8. Document scope-of-practice and standing orders. State-specific injector scope, documented training, standing orders signed by medical director.
9. Audit GLP-1 / weight-management compliance carefully. Compounded supplier verification, prescription protocols, clinical oversight.
10. Run a competitive process. Skytale, Cortes NLD, LaserAway, Ideal Image (NewSpring), Comvest, Caltius, Atlanta Capital, NaviMed, and the strategic manufacturer-backed players — a real auction with multiple buyers is worth 1-3 turns of EBITDA over single-bidder negotiation.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a MedSpa in 2026?

Sub-scale single-site MedSpas typically sell at 2x-4x SDE. Profitable single-location MedSpas with $500k-1.5M SDE go 3.5x-6x SDE. Small multi-site chains (2-5 locations, $1-3M EBITDA) go 5x-7x EBITDA. Mid-size regional platforms (5-15 locations) go 6x-9x EBITDA. Premium scale platforms (15+ locations, $8M+ EBITDA, CPOM-compliant, diversified service mix) reach 8x-10x+.

Who are the active buyers of MedSpas right now?

PE-backed platforms (the primary buyer pool): Skytale Group (the most visible consolidator with 100+ portfolio assets), LaserAway (200+ centers), Ideal Image (NewSpring Capital, 150+ centers), Cortes NLD. Manufacturer/strategic: AbbVie / Allergan Aesthetics (Botox, Juvederm, CoolSculpting), Hydrafacial / The Beauty Health Company (NASDAQ: SKIN), Galderma, Merz Pharma. PE sponsors directly: Comvest Partners, Caltius Equity Partners, NewSpring Capital, NaviMed Capital, Atlanta Capital, BlackRock-backed platforms.

What hurts a MedSpa’s valuation most?

Corporate-practice-of-medicine (CPOM) compliance gaps in CPOM-strict states, NP/PA scope-of-practice exposure, good-faith-exam workflow failures, GLP-1 / weight-management compliance issues, single-service-line concentration (especially commodity laser hair removal), owner-injector dependence, legacy operating systems or paper charts, undisclosed sale-of-goods vs. services revenue mix, and undocumented manufacturer rebate accruals.

What is corporate-practice-of-medicine (CPOM) and why does it matter?

CPOM is a state-level doctrine that restricts corporate ownership of medical practices. In CPOM-strict states (California, New Jersey, New York, Texas, and others), MedSpas typically operate through an MD-owned professional medical corporation (PC) for the clinical services and a separately-owned management services organization (MSO) for everything else. Structural CPOM gaps are a binary issue for many platform buyers.

Are GLP-1s (semaglutide, tirzepatide) a real revenue line for MedSpas?

Yes, but increasingly regulated. Compounded GLP-1 preparations have come under FDA enforcement scrutiny, and state compounding regulations vary. If GLP-1s are a meaningful revenue line, document supplier compliance, prescription protocols, clinical oversight, and the legal basis for compounded products carefully. Many buyers will discount or carve-out GLP-1 revenue depending on regulatory posture.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

How important is the operating system / EMR?

Very. Aesthetic Record is the dominant aesthetic-specific EMR; PatientNow, Symplast, Mangomint, and Boulevard are also common. Legacy systems or paper charts trigger a buyer-side integration discount. Modern operating systems also integrate with manufacturer rebate programs, patient loyalty (RepeatMD), and marketing stacks — all multiple-builders.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Lock in CPOM-compliant structure, build the injector bench, modernize EMR, document GFE workflows, diversify service mix, and enroll in manufacturer rebate programs.

Related research

• How to sell a dermatology practice
• How to sell a dental practice
• How to sell a veterinary practice
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell a behavioral health practice
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Private equity value creation
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch